XML 203 R130.htm IDEA: XBRL DOCUMENT v3.22.4
Provisions and other non-current liabilities (Details 3)
$ in Millions
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Disclosure of other provisions [line items]      
Product liability, government investigations, other legal matters provisions $ 154.0 $ 341.0 $ 181.0
Italy | Lucentis [member]      
Disclosure of other provisions [line items]      
Estimated financial effect of contingent liabilities, maximum fine 1,300.0    
Estimated financial effect of contingent liabilities, damages claimed 330.0    
Italy | NAG and Novartis Pharma SpA [member] | Lucentis [member]      
Disclosure of other provisions [line items]      
Estimated financial effect of contingent liabilities 125.0    
US | Exforge Group [member]      
Disclosure of other provisions [line items]      
Amount of settlement in principle $ 245.0    
US | Sandoz [member]      
Disclosure of other provisions [line items]      
Description of nature of obligation contingent liabilities, number of states with alleged violations 50    
Amount of settlement in principle   185.0 195.0
US | Sandoz [member] | Taxotere [member]      
Disclosure of other provisions [line items]      
Product liability contingency, loss exposure not accrued, number of cases 3,100    
US | Sandoz [member] | Amiodarone [member]      
Disclosure of other provisions [line items]      
Product liability contingency, loss exposure not accrued, number of cases 2    
US | NPC and others [member] | Reclast/Aclasta [member]      
Disclosure of other provisions [line items]      
Product liability contingency, loss exposure not accrued, number of cases 20    
US | NPC and others [member] | Tasigna [member]      
Disclosure of other provisions [line items]      
Product liability contingency, loss exposure not accrued, number of cases 400    
France | F Hoffman La Roche AG and Roche SpA [member]      
Disclosure of other provisions [line items]      
Estimated financial effect of contingent liabilities, maximum fine     $ 452.0
Greece | Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]      
Disclosure of other provisions [line items]      
Estimated financial effect of contingent liabilities, maximum fine   $ 1.2  
Estimated financial effect of contingent liabilities, compensation for moral damages $ 225.0